Türkeş, Ayşın Zeytinoğlu

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/7553
Name Variants
Ayşın Zeytinoğlu
Turkes, AZ
Turkes, Aysin Zeytinoglu
Aysin Zeytinoglu Turkes
Ayşın Zeytinoğlu Türkeş
Job Title
Email Address
aysin.zeytinoglu@ieu.edu.tr
Main Affiliation
09.02. Internal Sciences
Status
Current Staff
Website
ORCID ID
0000-0003-4174-9539
Scopus Author ID
6602884995
Turkish CoHE Profile ID
98A79C7720AF5E84
Google Scholar ID
0Ki-KxYAAAAJ
WoS Researcher ID
W-8512-2019
Files
aysin.jpg (7.2 KB)

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
3
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents

49

Citations

557

h-index

13

Go to Scopus profile
Documents

55

Citations

477

Go to WoS profile
Scholarly Output

3

Articles

3

Views / Downloads

8/21

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

1

Scopus Citation Count

1

Patents

0

Projects

2

WoS Citations per Publication

0.33

Scopus Citations per Publication

0.33

Open Access Source

2

Supervised Theses

0

JournalCount
Türk Mikrobiyoloji Cemiyeti Dergisi1
Vaccine1
Vaccines1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

20243
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Article
    Evaluation of Antibody Responses in Healthcare Workers Before & After Meningococcal Vaccine and Determination of Meningococcal Carriage Rates
    (Elsevier Ltd, 2024-07) Baskol, Elik, D.; Yıldırım, C.; Akyol, Seyhan, D.; Aytac, Erdem, H.; Zeytinoglu, A.; Pullukcu, H.; Aydemir, S.S.; Elik, Dilsah Baskol; Seyhan, Deniz Akyol; Baskol Elik, Dilsah; Akyol Seyhan, Deniz; Aytac Erdem, Huseyin; Erdem, Huseyin Aytac; Tasbakan, Meltem
    The rates of nasopharyngeal meningococcal carriage in healthcare workers are unknown. Meningococcal vaccine is recommended for risk groups but healthcare workers are not included in risk groups for many countries. Herein, we aimed to investigate the nasopharyngeal meningococcal carriage rates, basal and after one dose of Men-ACWY-DT vaccine response on the 30th day by evaluating meningococcus IgG antibody levels and decolonization at month six after vaccination among the detected carriers. Nasopharyngeal swab samples were taken before vaccination to evaluate meningococcal carriage in healthcare workers. All participants received a single dose of Men-ACWY-DT vaccine. Serum samples were collected immediately before vaccination and again on day 30 post-vaccination. Antibodies in the stored sera were analyzed using the ELISA method. Participants who were determined to carry meningococci at the initial visit underwent another round of nasopharyngeal swab tests six months post-vaccination to check for decolonization. Between November 2020 and May 2021, we evaluated samples from 100 physicians [52 % females, 28.28 ± 4.45 (min: 24, max: 49)]. The majority of the physicians worked in the emergency department (45 %), followed by the infectious diseases clinic (14 %). Fifty-eight physicians had a history of at least one contact with a meningococcus-infected patient, and 53 (91.4 %) had used prophylactic antibiotics at least once due to this exposure. None of the study group nasopharyngeal swab cultures were positive for Neisseria meningitidis. Before the Men-ACWY-DT vaccine, anti-meningococcus IgG positivity was detected in the serum samples of only 3 (3 %) participants. By day 30 after vaccination, 48 % of participants showed positive for antibodies. As we didn't detect nasopharyngeal carriage in any participants, we didn't evaluate decolonization among carriers six months post-vaccination. Notably, detection of antibodies was evident in about half of the participants on day 30 after receiving a single dose of the Men-ACWY-DT vaccine. © 2024 Elsevier Ltd
  • Thumbnail Image
    Article
    Citation - WoS: 1
    Citation - Scopus: 1
    Covid-19 Antibody Levels Among Various Vaccination Groups, One-Year Antibody Follow-Up in Two University Hospitals From Western and Central Turkey
    (Mdpi, 2024-01-07) Soylu, Mehmet; Sağıroğlu, Pınar; Ozarslan, Muhammed Alper; Acet, Oguzhan; Yüce, Zeynep Tuere; İzci Çetinkaya, Feyza; Durmaz, Seyfi; Türkeş, Ayşın Zeytinoğlu; Erensoy, Memnune Selda
    Various clinical outcomes, reinfections, vaccination programs, and antibody responses resulted from the COVID-19 pandemic. This study investigated the time-dependent changes in SARS-CoV-2 antibody responses in infected and/or vaccinated and unvaccinated individuals and to provide insights into spike and nucleocapsid antibodies, which fluctuate during infectious and non-infectious states. This cohort study was carried out at the Ege University Faculty of Medicine hospital in Izmir (western Turkey) and the Erciyes University Faculty of Medicine hospital in Kayseri (central Turkey) between December 2021 and January 2023, which coincided with the second half of COVID-19 pandemic. The study included 100 COVID-19 PCR-positive patients and 190 healthcare workers (HCWs). Antibody levels were followed up via quantitative anti-SARS-CoV-2 spike and qualitative anti-nucleocapsid immunoassays (Elecsys (TM)). Antibody levels declined after infection but persisted for at least 6-8 months. Individuals who had received only CoronaVac had higher anti-nucleocapsid antibody levels in the early months than those who received mixed vaccination. However, anti-spike antibodies persisted longer and at higher levels in individuals who had received mixed vaccinations. This suggests that combining two different vaccine platforms may provide a synergistic effect, resulting in more durable and broad-spectrum immunity against SARS-CoV-2. The study provides information about the vaccination and antibody status of healthcare workers in the second half of the pandemic and provides valuable insights into the dynamics of antibody responses to COVID-19 infection and vaccination.
  • Thumbnail Image
    Article
    Hepatit C Serolojik Tanısında Anti-HCV Antikoru Düşük Pozitif ve Sınır Değerlerin İki Farklı Enzim İmmunoassay Yöntemiyle Değerlendirilmesi
    (2024) Zeytınoglu, Aysın; Soylu, Mehmet; Uysal, Ayça Aydın
    Amaç: Hepatit C virüsü (HCV) akut ve kronik hepatit tablolarında rol oynayan bir viral etkendir. HCV enfeksiyonunun tanısında en sık başvurulan yöntemler anti-HCV antikorlarının saptanması, alanin transaminaz düzeylerinin (ALT) ölçülmesi ve HCV-RNA pozitifliği değerlendirilmesidir. Bu çalışmada kanda iki farklı enzim immünoassay tabanlı test olan enzim bağlı floresan test (ELFA) ve kemilüminesans immün assay (CLIA) yöntemlerinin en az birinde sınır değer ve zayıf pozitiflik olarak değerlendirilen hastaların HCV antikor indeks değerleri ile olguların ALT ve HCV-RNA sonuçları karşılaştırılmıştır. Yöntem: Ekim 2018-Kasım 2019 tarihleri arasında hastanemize başvuran 59 hastanın serum örneklerinin CLIA sistemindeki sinyal/cut-off (S/CO) ve ELFA sistemindeki Test Value (TV) değerlerine göre zayıf pozitif ve sınır değer sonuçlar çalışmaya dahil edildi. Bulgular: Serum örneklerinden elde edilen HCV antikorları için S/CO ve TV ortalamaları; ELFA testi için 2.78 TV, CLIA testi için ortalama 2.32 S/CO olarak saptandı. Tüm serum örneklerinin ALT düzeyi ortalaması 28.7 U/L olarak saptandı. ELFA testi ile negatif sonuç verilen 17 hastanın (11 Kadın- 6 Erkek, yaş ortalamaları: 42.2) serum örneklerinde CLIA testi ile zayıf pozitif sonuç elde edildi ve ELFA testi ortalaması 0.24 TV, CLIA testi ortalaması 1.74 S/CO olarak saptandı. ELFA testinde sınır değer olguların ortalaması 0.82 TV; aynı grupta CLIA ortalaması 1.97 S/CO olarak saptandı. Sonuç: Bir sistemle elde edilen HCV antikoru sonuçlarının; zayıf pozitif ve sınır değer sonuçların olanak varsa farklı bir sistemle tekrarı ve HCV-RNA testi ile doğrulanması önerilmekle birlikte pozitiflik için baz alınan “1 S/ CO” ve “1 TV” değerlerinin daha yüksek seviyelere çekilmesinin ileri çalışmalarla desteklenmesi gerekmektedir.